FGFR2

A gene on chromosome 10q25.3-q26 that encodes fibroblast growth factor receptor-3, which has an extracellular region composed of 3 immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. Binding of a ligand unleashes a cascade of downstream signals that impact on mitogenesis and differentiation.

Molecular pathology
FGFR3 mutations are associated with Apert syndrome, Beare-Stevenson cutis gyrata syndrome, Crouzon syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome, Saethre-Chotzen syndrome and syndromic craniosynostosis.

Mentioned in ?

References in periodicals archive ?

The FGFR2 gene encodes keratinocyte growth factor receptor involved in the proliferation of keratinocytes and wound healing, while the TNFA gene encodes a wellknown proinflammatory cytokine.

Chronic nonhealing wounds: could leg ulcers be hereditary?

As for the role of FGFR in lens regeneration, the bek isoform of FGFR2 was shown to be present in Xenopus epidermis only in regions where the epidermis was capable of transdifferentiating into lenses (Arresta et al., 2005).

FGF signaling is required for lens regeneration in Xenopus laevis

We decided to investigate the expression of both FGFR2 isoforms in ASCs, through absolute quantification of transcripts by qRT-PCR.

Neuropilin 1 Mediates Keratinocyte Growth Factor Signaling in Adipose-Derived Stem Cells: Potential Involvement in Adipogenesis

Sequence analysis was performed on 2 exons (exons 7-8) of the FGFR2 gene in 85 cases referred for pre-diagnosis of craniosynostosis between 2010 and 2016.

FGFR2 Gene Mutations in Patients with Syndromic or Isolated Craniosynostosis

The group of Florence Bareyre has shown that FGF22 signalling via FGFR1 and FGFR2 is essential for the formation of these new synapses [82].

The Function of FGFR1 Signalling in the Spinal Cord: Therapeutic Approaches Using FGFR1 Ligands after Spinal Cord Injury

(c) ln RR: regression coefficients of each SNP from simple logistic regression, adjusted for age, menarche, menopause, family history, pregnancy, histology, treatment, the FGFR2 GWAS-identified SNP, and deleterious variants in ATM, BRCA1, BRCA2, CHECK2, and offset term.

A bayesian hierarchical model for relating multiple snps within multiple genes to disease risk

AKT1 CTNNB1 FGFR1 GNAS KRAS NRAS PIK3R5 STAT1 AKT2 EGFR FGFR2 HRAS MAP2K1 NTRK1 PKHD1 TEC AKT3 ERBB2 FGFR3 IDH1 MAP2K2 NTRK2 PRKCB1 TP53 (HER2) ALK ERCC6 FGFR4 IDH2 MAP2K7 NTRK3 RAF1 BRAF FBX4 FOXL2 IGF1R MET PDGFRA RET CDK4 FBXW7 GNA11 KDR MYC PIK3R1 SMO CSF1R FES GNAQ KIT NEK9 PIK3R4 SOS1

MDM2 amplification and PI3KCA mutation in a case of sclerosing rhabdomyosarcoma

The differences in the EDAR and FGFR2 genes were identified last year and are thought to have occurred as part of the evolution of Asian populations following their prehistoric divergence from Europeans.

Why do some people have curly hair

The majority of family clusters are not attributable to any of these high-risk susceptibility genes and attention has recently turned to 'low-risk' genes such as FGFR2 and TNCR9, which may collectively be responsible for up to 25% of familial breast cancer [32].

Managing the contralateral breast in a gene mutation carrier with breast cancer

Novel roles of Fgfr2 in AER differentiation and positioning of the dorsoventral limb interface.

Recent progress in biotechnology-based gene manipulating systems to produce knock-in/out mouse models

Food and Drug Administration granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy.

United States : FDA approves first targeted therapy for metastatic bladder cancer

The company added that BLU-554 (CS3008) is an oral, potent highly selective and irreversible inhibitor of FGFR4, with a precise selectivity for FGFR4 that spares the paralog kinases FGFR1, FGFR2 and FGFR3.

CStone wins CTA's approval in China to begin Phase I trial for FGFR4 inhibitor BLU-554 (CS3008)